Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

4 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 3

2(25.0%)

Phase 2

2(25.0%)

8Total

Phase 1(4)

Phase 3(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06525220Phase 3Recruiting

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

Role: lead

NCT07353957Phase 2Recruiting

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

Role: lead

NCT06496178Phase 3Recruiting

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Role: lead

NCT04868877Phase 1Active Not Recruiting

Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

Role: lead

NCT04100694Unknown

Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor

Role: lead

NCT03038230Phase 1Terminated

MCLA-117 in Acute Myelogenous Leukemia

Role: lead

NCT03526835Phase 1Recruiting

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Role: lead

NCT03922204Phase 1Completed

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies